美敦力发布强劲的第三季度FY26财报，超出收入和EPS指南，伴随着关键产品上市

summarizeSummary

Medtronic plc delivered a strong third quarter, surpassing both revenue and non-GAAP EPS guidance. The company's 6.0% organic revenue growth, coupled with an 8.7% reported increase to $9.017 billion, demonstrates robust operational performance. Key drivers include exceptional growth in the Cardiovascular portfolio, particularly Cardiac Ablation Solutions, which surged 80% year-over-year. Significant regulatory milestones, such as U.S. FDA clearance for the Hugo™ robotic-assisted surgery system and Stealth AXiS™ Surgical System, alongside a CE Mark for Sphere-360™, highlight a strong innovation pipeline. The reaffirmation of full-year FY26 organic revenue and non-GAAP EPS guidance, despite the strong Q3 beat, suggests management's confidence in sustained performance. This filing indicates positive momentum for Medtronic, driven by strategic investments in high-growth opportunities and successful product commercialization.

check_boxKey Events

• 超出了 Q3 FY26 财务指南

  美敦力公司报告了第三季度收入9.017亿美元，同比增长8.7%，同店增长6.0%，超过指导目标50个基点。非GAAP稀释每股收益1.36美元，高于指导目标中点3美分。

• 心血管产品业务强劲增长

  心血管业务收入增长了10.6%，以自有增长的形式实现，心脏消融解决方案同比增长80%，包括137%的美国增长，得益于其脉冲场消融产品组合。

• 关键产品获批和上市

  该公司获得了球面-360™的CE标志，并启动了其关键试验，包括了对Hugo™机器人辅助外科系统和Stealth AXiS™脊柱手术系统的美国FDA批准。

• 糖尿病业务展现出强劲的国际增长

  糖尿病收入增长8.3%，主要是由于国际市场的两位数增长。

auto_awesomeAnalysis

Medtronic plc delivered a strong third quarter, surpassing both revenue and non-GAAP EPS guidance. The company's 6.0% organic revenue growth, coupled with an 8.7% reported increase to $9.017 billion, demonstrates robust operational performance. Key drivers include exceptional growth in the Cardiovascular portfolio, particularly Cardiac Ablation Solutions, which surged 80% year-over-year. Significant regulatory milestones, such as U.S. FDA clearance for the Hugo™ robotic-assisted surgery system and Stealth AXiS™ Surgical System, alongside a CE Mark for Sphere-360™, highlight a strong innovation pipeline. The reaffirmation of full-year FY26 organic revenue and non-GAAP EPS guidance, despite the strong Q3 beat, suggests management's confidence in sustained performance. This filing indicates positive momentum for Medtronic, driven by strategic investments in high-growth opportunities and successful product commercialization.